Nationwide population-based study of the impact of immediate breast reconstruction after mastectomy on the timing of adjuvant chemotherapy.

CONCLUSION: Postmastectomy IBR marginally reduced the likelihood of receiving adjuvant chemotherapy within 6 weeks, but not within 9 or 12 weeks. Thus, IBR is not contraindicated in patients who need adjuvant chemotherapy after mastectomy. PMID: 31386193 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31386193?dopt=Abstract

Source: The British Journal of Surgery - August 5, 2019 Category: Surgery Authors: Heeg E, Harmeling JX, Becherer BE, Marang-van de Mheen PJ, Vrancken Peeters MTFD, Mureau MAM Tags: Br J Surg Source Type: research